MARKET

GNCA

GNCA

Genocea
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.010
-0.060
-1.95%
Closed 19:03 03/02 EST
OPEN
3.090
PREV CLOSE
3.070
HIGH
3.120
LOW
3.000
VOLUME
235.36K
TURNOVER
--
52 WEEK HIGH
5.75
52 WEEK LOW
1.100
MARKET CAP
161.09M
P/E (TTM)
-2.4878
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Genocea to Present at the H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mar 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a...
GlobeNewswire · 12h ago
Streptococcus Pneumoniae Vaccine Market Global Market Size, Share, Growth, Demand ,Trends and Forecast,2020 -2027 By Ameco Research
pune, India, Fri, 26 Feb 2021 00:16:21 / Comserve Inc. / -- The global Streptococcus Pneumoniae Vaccine market is segmented by company, region (country), by...
Comserve · 5d ago
Cancer Vaccines Market Size to Surpass US$ 8.5 billion by 2025
Feb 25, 2021 (Market Insight Reports) -- Selbyville, Delaware According to the business intelligence report titled 'Cancer Vaccines Market, Pipeline Analysis...
Market Insight Reports · 6d ago
10-K: GENOCEA BIOSCIENCES, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 02/22 21:39
Global Epstein-Barr Virus (HHV-4) Infections Treatment Market 2021 with Strategies to Boost Growth, Covid-19 Impact Analysis, Size & Share, Industry Statistics, Trends Evaluation, Geographical Segmentation, Business Challenges till 2027
Feb 15, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Epstein-Barr Virus (HHV-4)...
The Express Wire · 02/15 05:14
DJ Genocea Biosciences Price Target Cut to $6.00/Share From $7.00 by Needham
Dow Jones · 02/11 16:25
DJ Genocea Biosciences Is Maintained at Buy by Needham
Dow Jones · 02/11 16:25
H.C. Wainwright Keeps a Buy Rating on Genocea Biosciences (GNCA)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Genocea Biosciences (GNCA) today and set a price target of $9.00. The company's shares
SmarterAnalyst · 02/11 16:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNCA. Analyze the recent business situations of Genocea through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNCA stock price target is 6.48 with a high estimate of 9.00 and a low estimate of 4.400.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 32.61M
% Owned: 60.93%
Shares Outstanding: 53.52M
TypeInstitutionsShares
Increased
13
2.54M
New
18
1.50M
Decreased
4
16.62K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.03%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Director
William Clark
Chief Financial Officer
Diantha Duvall
Senior Vice President
Narinderjeet Singh
Chief Scientific Officer
Jessica Flechtner
Senior Vice President
Narinder Singh
Other
Girish Aakalu
Other
Thomas Davis
Director
Gisela Schwab
Independent Director
Ali Behbahani
Independent Director
Katrine Bosley
Independent Director
Ronald Cooper
Independent Director
Michael Higgins
Independent Director
George Siber
  • Dividends
  • Splits
  • Insider Activity
No Data
About GNCA
Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. It provides GEN-009 program, which is a neoantigen vaccine candidate. The Company is conducting a Phase 1/2a clinical trial across a range of solid tumor types. It also provides GEN-011, which is a neoantigen-specific adoptive T cell therapy.

Webull offers kinds of Genocea Biosciences Inc stock information, including NASDAQ:GNCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNCA stock methods without spending real money on the virtual paper trading platform.